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Background: Erlotinib (TARCEVA®) is an oral, epidermal growth 
factor receptor (EGFR) tyrosine kinase inhibitor that has anti-tumor 
activity and good tolerability in non-small cell lung cancer (NSCLC). 
In particular, higher response rates have been noted in Oriental patients 
than Western patients. The aim of this study (EAP; Expanded Ac-
cess Program) is to evaluate the efﬁcacy and tolerability of erlotinib 
monotherapy as a palliative treatment for advanced NSCLC patients in 
Korea. 
Material and Methods: Patients with histologically or cytologically 
conﬁrmed stage IIIB or IV NSCLC including recurrent, or metastatic 
disease, with performance status from 0 to 3, were eligible either if they 
had received any anti-cancer treatment except EGFR inhibitors or if 
they were unsuitable for chemotherapy due to poor performance status. 
Enrolled patietns were treated with oral erlotinib, at a dose of 150 mg 
daily until disease progression or development of intolerable toxicity. 
Results: The median age of the 120 patients was 61 years, and 63.3% 
were male; 89.1% were performance status 0-1; 50.8% had received 
one prior palliative chemotherapy regimens and 33.3% were two or 
more prior palliative regimens. Overall tumor response rate, including 
complete and partial response, was 23.3% and an additional 18.3% 
of patients achieved stable disease. Superior tumor responses were 
observed in females (p=0.001), never-smokers (p=0.047), and histology 
of adenocarcinoma (p<0.001). The most common adverse event was 
skin rash (78%), which were generally mild, but grade 3/4 skin rash 
occurred in 13% of all enrolled patietns. There is one treatment related 
mortality with pneumonia. With a median follow-up of 14.5 months, 
the median time to progression (TTP) was 2.7 months (95%CI; 2.2-3.2) 
and the median overall survival (OS) has not been reached yet. Female 
(p<0.001), adenocarcinoma (p=0.01), never-smoker (p<0.001), and ap-
pearance of skin rash (p<0.001) were good prognostic factor for overall 
survival. In multivariate analysis, female gender and presented skin 
rash were better prognostic factors for survival. 
Conclusion: Erlotinib monotherapy showed clinically signiﬁcant 
anti-tumor activity and an acceptable tolerability proﬁle as a palliative 
treatment in advanced NSCLC patients in Korea, especially in females, 
never-smokers, patients with adenocarcinoma histology, and in cases 
with skin rash. 
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Background: Mutations in epidermal growth factor receptor (EGFR) 
are considered as a strong predictive marker to EGFR tyrosine kinase 
inhibitors (TKIs) in non-small-cell lung cancer (NSCLC). Recent stud-
ies suggested EGFR status may change between primary tumor and 
corresponding metastatic site. However, it has not fully been evaluated 
whether EGFR mutation differs in metastases compared to primary 
NSCLC.
Methods: In total, 128 tumor samples from 64 NSCLC patients who 
underwent surgery between 1996 and 1999 were investigated compar-
ing matched 64 primary tumors, and 64 lymph node metastases. The 
epidermal growth factor receptor mutation status was analyzed by a 
direct sequencing method (exons 18-21 in EGFR) on tumor samples of 
primary NSCLC and corresponding lymph node metastasis.
Results: In 17.2% of patents (11/64), EGFR mutation was identiﬁed in 
either primary NSCLC or metastasis by DNA sequencing. Six (54.5%) 
out of eleven cases showed discordance of EGFR mutation in the 
primary tumor/metastasis site. Two cases showed EGFR mutation in 
the metastasis but not in the primary tumor, while, in four cases, EGFR 
mutation was detected in the primary tumor but not in the metastasis 
site. The majority of discordance of EGFR mutations was identiﬁed 
in exon 19 (83.3%, 5/6). The median overall survival (OS) was 17.7 
months (95% conﬁdence interval, 9.4-20.0). Median OS was not varied 
by the discordance of EGFR mutation status between primary NSCLC 
and corresponding metastatic site.
Conclusions: These results suggest that the status of EGFR mutation 
in primary NSCLC and that in corresponding metastasis site varied in 
considerable cases by direct DNA sequencing. Whether the status of 
EGFR mutation changes during the process of metastasis remains to be 
investigated. The data will be updated with larger number of speci-
mens. 
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Background: Epidermal growth factor receptor (EGFR) muta-
tions have been reported to be related to geﬁtinib responsiveness in 
non-small cell lung cancer (NSCLC). This exploratory analysis was 
performed within a prospective phase II study to determine the associa-
tion of EGFR mutations with clinical characteristics and outcome in 
NSCLC patients who were treated with geﬁtinib.
Methods: We analyzed the incidence of EGFR mutations in NSCLC 
specimens from 68 Korean patients who were treated with geﬁtinib 
(43 patients as second-line and 25 as third-line therapy) in a prospec-
tive study. Thirty-nine tumor tissue samples were obtained from these 
patients and analyzed for EGFR mutations (exons 18 to 21). The 
molecular alterations were compared with clinical characteristics and 
outcomes.
Results: EGFR mutations were found in 7 (18%) out of 39 patients, 
including in-frame deletions within exon 19 (n=3) and L858R missence 
mutaions in exon 21 (n=4). For the 7 patients with EGFR mutations, 6 
were male, 6 were current/former smoker, and 4 had adenocarcinoma. 
Higher rate of response to geﬁtinib was noted in patients with EGFR 
mutations compared to those with wild-type EGFR (86% vs. 16%, 
respectively; p=0.001). Using a multiple logistic regression model 
performed by entering all predictive factors as covariates, only the 
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presence of EGFR mutations (odds ratio, 0.019; 95% CI, 0.001-0.298; 
P=0.005) was signiﬁcantly associated with the higher response rate to 
geﬁtinib. Progression-free survival (6.6 vs. 3.3 months; p=0.246) and 
overall survival (8.1 vs. 8.6 months; p=0.397) were similar between 
patients with EGFR mutations and those with wild-type EGFR.
Conclusion: Clinical response to geﬁtinib in this study was linked to 
the presence of EGFR mutations. Given the limitation of small sample 
size, EGFR mutations were not associated with the speciﬁc clinical 
predictors for geﬁtinib responsiveness.
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Background: Retrospective analyses of previous trials have shown the 
clinical advantage of geﬁtinib in advanced non-small cell lung cancer 
(NSCLC) patients with certain favorable baseline factors (Asian ethnic-
ity, female, adenocarcinoma, or no smoking history). This prospective 
phase II study was designed to test the hypothesis that higher response 
rates might be achieved if patients are selected according to these clini-
cal predictors for response.
Methods: Korean NSCLC patients who have failed after docetaxel-
based ﬁrst-line chemotherapy were consecutively accrued. Patients 
without any of the favorable clinical predictors (i.e., male smoker with 
non-adenocarcinoma) received irinotecan 100 mg/m2 on days 1, 8 and 
15 every 4 weeks (irinotecan arm). Patients who had at least one of the 
predictors for response received geﬁtinib 250 mg/d orally from day 1 
(geﬁtinib arm). Primary endpoint was response rate. With a two-stage 
phase II design, the required number of patients was at least 25 per 
each arm.
Results: Of 68 patients accrued, 25 were treated with irinotecan and 
43 with geﬁtinib. In the geﬁtinib arm, 22 patients were female, 20 were 
never-smoker, and 33 had adenocarcinoma. Treatment duration was 
signiﬁcantly longer in the geﬁtinib arm (2.0 months for irinotecan arm 
v 3.9 months for geﬁtinib arm; p<0.01). Median number of chemother-
apy cycles was 2 (range, 1-6) for irinotecan arm. Fewer drug-related 
toxicities were observed with geﬁtinib compared with irinotecan. In 
the irinotecan and geﬁtinib arm, 36% and 9% of patients, respectively, 
discontinued treatment because of toxicity. The objective responses of 
irinotecan and geﬁtinib arm were 16% (95% CI, 2-30) and 40% (95% 
CI, 25-54), respectively (p=0.04). Patients in the geﬁtinib arm had a 
longer (p=0.04), progression-free survival (5.3 months; 95% CI, 1.7-
8.8) than those in the irinotecan arm (3.2 months; 95% CI, 1.7-4.6).
Conclusion: Geﬁtinib could be a reasonable second-line option in Ko-
rean NSCLC patients who had at least one favorable clinical predictor.
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Background: Erlotinib is an orally active and selective inhibitor of 
HER1/EGFR tyrosine kinase, which gained approval for the treat-
ment of previously treated patients with advanced non-small cell lung 
cancer (NSCLC). The randomized, phase III study BR.21 demonstrated 
a signiﬁcant survival beneﬁt for patients with advanced NSCLC who 
received erlotinib versus placebo (HR: 0.70, 95% CI 0.58–0.85), after 
failure to one or more previous treatments. The TargeT trial is a large, 
Spanish, non-randomized, phase II trial evaluating the efﬁcacy and 
safety of erlotinib in patients with advanced or metastatic NSCLC.
Methods: Patients with previously treated advanced or metastatic 
NSCLC or patients that were not suitable for ﬁrst line conventional 
chemotherapy, stage IIIB/IV, PS 0-2 were enrolled to receive oral erlo-
tinib 150 mg/day until disease progression or withdrawal. The primary 
endpoint of the study was time to progression (TTP) in the intent to 
treat (ITT) population. 
Results: 1,796 patients were enrolled from June 04 to March 06 and 
1,539 evaluated for this analysis. Demographics: median age 65 y 
[range 26–95]; male: 72%; stage IV: 82%; PS 0/1/2: 21%/54%/25%; 
adenocarcinoma histology: 53%, SCC: 25.0%, LCC: 16%, other: 6%; 
current/former smoker: 78%. Patients receiving erlotinib as 1st/2nd/
≥3rd line were 29%/39%/33%, respectively. 879 were analyzed for 
response: 11 patients reached CR (1%), 154 PR (18%), for and overall 
response rate of 19%. Control disease rate was 58%.
In the exploratory subgroup analysis, higher response rate (RR) was 
related to female gender (35.9% vs. 11.1%; p<0.0001), the absence 
of smoking habits (42.2% vs. 11.7%; p<0.0001) and adenocarcinoma 
histology (25.8 vs. 11.4; p<0.0001). Patients receiving erlotinib in the 
ﬁrst line setting reached signiﬁcantly higher RRs (31.5%) than in fur-
ther lines of treatment (13.8%; p<0.0001). All these factors remained 
as predictive factors for response in the multivariate analysis, with 
the exception of gender. Similar results were found regarding control 
disease rate. 
In the ITT population, median time to progression was 3.9 months 
[95% CI 3.5–4.4] and median overall survival 6.1 months [95% CI 
5.5–6.4 months]. Statistically signiﬁcant differences were found in 
favor of nonsmokers (TTP and OS: p<0.0001), patients with a good 
performance status (TTP: p=0.004; OS: p<0.0001) and adenocarcinoma 
(for the comparison with other grouped histologies; TTP: p=0.002; 
OS: p<0.0001), both in the univariate and multivariate analysis (p 
refers to the latter analysis). Interestingly, no differences between 
adenocarcinoma and SCC speciﬁcally were detected. Treatment in the 
ﬁrst line setting was also associated with longer TTP in the Cox model 
(P=0.002), but not with longer survival. Finally, female gender did not 
signiﬁcantly associate with TTP or survival.
